UNSPSC 51183001: Corticotropin/zinc hydroxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS701. This VA Drug Class (HS701) classifies this compound as belonging to the group ANTERIOR PITUITARY.

UNSPSC 51183001 Corticotropin/zinc hydroxide is a Commodity code covering pharmaceutical ingredients and finished pharmaceutical products that state and local governments procure through cooperative purchasing agreements and direct supply contracts. State and local health agencies, correctional facilities, public hospitals, and other government health systems source generic multi-source pharmaceuticals and over-the-counter products under this code, working through established wholesaler networks with manufacturers required to maintain cGMP and Drug Supply Chain Security Act compliance, hold current FDA approvals, and meet strict product availability and shelf-life standards. Issuing bodies include state purchasing offices administering multistate cooperative agreements, state health departments, and participating local government health facilities; the Minnesota Department of Administration's Office of State Procurement serves as a primary coordinator for this activity through its role administering cooperative purchasing frameworks that span multiple states.

The code shows recent activity centered in Minnesota through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, posted January 20, 2026, with proposals due March 26, 2026. The MMCAP solicitation establishes multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with vendors required to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must submit pricing and detailed product information (National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, and manufacturing locations); evaluation is weighted heavily on price competitiveness (75 percent) with secondary weight on fixed pricing, EDI capability, administrative fee compliance, and administrative format requirements. The contract term extends two years for new responders with optional extensions through June 30, 2028 for incumbent responders, with awarded vendors providing all products to wholesalers by May 15, 2026, effective July 1, 2026.